ArticleJournal of hepatocellular carcinoma2026
PUM1 Promotes HCC Cell Proliferation and Inhibits Mitochondria‑mediated Apoptosis, Accompanied by Activation of the PI3K-AKT Pathway.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Belonging to the RNA-binding protein family, Pumilio RNA binding family member 1 (PUM1) modulates gene expression post-transcriptionally through the recognition of particular motifs within the 3' untranslated region of its target transcripts. The present investigation seeks to elucidate PUM1's contribution to HCC pathogenesis and advancement, while also probing the molecular mechanisms that underpin its function. Methods: Publicly available datasets were employed to examine PUM1 transcript abundance in hepatocellular carcinoma, along with its relationship to clinicopathological parameters and prognostic outcomes. PUM1 protein levels were subsequently corroborated in clinical HCC specimens via immunoblotting and immunohistochemical staining. To explore the biological functions of PUM1, we established HCCLM3 cell lines with PUM1 overexpression and knockdown. We then evaluated proliferation via EdU, colony formation, and CCK‑8 assays; apoptosis via TUNEL and flow cytometry; mitochondrial membrane integrity and calcium balance using JC‑1, Mito‑Tracker, and Rhod‑2; and oxygen species (ROS) accumulation via MitoSOX and DCFH‑DA. The downstream molecular pathways were further examined by Western blotting. Results: HCC tissues exhibit markedly upregulated PUM1 levels, a feature tightly correlated with poor prognosis. In vitro, PUM1 preserved mitochondrial membrane integrity and calcium homeostasis in HCC cells, while suppressing the accumulation of reactive oxygen species (ROS). Additionally, PUM1 inhibited programmed cell death and promoted cell proliferation. These biological activities were closely associated with the PI3K-AKT signaling pathway. Conversely, knockdown of PUM1 significantly impaired HCC cell proliferation and induced apoptosis. Conclusion: PUM1 promotes HCC cell proliferation and suppresses mitochondria‑mediated apoptosis, effects that are closely associated with activation of the PI3K-AKT pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.